{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:46:01Z","timestamp":1790837161369,"version":"4.1.0"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02759","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T04:17:20Z","timestamp":1543983440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":75,"title":["Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Mandy","family":"van Gulijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"Dammeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Vroman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","article-title":"Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species","volume":"45","author":"Guilliams","year":"2016","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1136\/jim-2016-000072","article-title":"Identification and characterization of human dendritic cell subsets in the steady state: a review of our current knowledge","volume":"64","author":"Patel","year":"2016","journal-title":"J Investig Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12026-017-8931-1","article-title":"Dendritic cell-based immunotherapy: a basic review and recent advances","volume":"65","author":"Constantino","year":"2017","journal-title":"Immunol Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fimmu.2014.00055","volume":"5","author":"Hopp","year":"2014","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev.iy.09.040191.001415","article-title":"The dendritic cell system and its role in immunogenicity","volume":"9","author":"Steinman","year":"1991","journal-title":"Annu Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic cell-based immunotherapy: state of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/blood-2004-06-2492","article-title":"Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells","volume":"105","author":"M\u00fcnz","year":"2005","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4049\/jimmunol.172.1.464","article-title":"Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer","volume":"172","author":"Nefedova","year":"2004","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00018-016-2317-8","article-title":"Molecular mechanisms involved in dendritic cell dysfunction in cancer","volume":"74","author":"Tang","year":"2017","journal-title":"Cell Mol Life Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1440-1711.2005.01371.x","article-title":"Dendritic cell dysfunction in cancer: a mechanism for immunosuppression","volume":"83","author":"Pinzon-Charry","year":"2005","journal-title":"Immunol Cell Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","article-title":"Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives","volume":"168","author":"Constantino","year":"2016","journal-title":"Transl Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI69999","article-title":"Targeting immunosuppression for cancer therapy","volume":"123","author":"Ghirelli","year":"2013","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","article-title":"The determinants of tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fimmu.2013.00417","article-title":"Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for dc vaccination: a game of stop and go","volume":"4","author":"Vasaturo","year":"2013","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e25961","DOI":"10.4161\/onci.25961","article-title":"Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy","volume":"2","author":"Devaud","year":"2013","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.critrevonc.2016.09.002","article-title":"Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses","volume":"107","author":"Seyfizadeh","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-08-2729","article-title":"Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients","volume":"15","author":"Verdijk","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","article-title":"Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha","volume":"179","author":"Sallusto","year":"1994","journal-title":"J Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"13720","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CJI.0000000000000063","article-title":"A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer","volume":"38","author":"Prue","year":"2015","journal-title":"J Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00002371-200207000-00001","article-title":"Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity","volume":"25","author":"Zhou","year":"2002","journal-title":"J Immunother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","article-title":"Antigens for cancer immunotherapy","volume":"20","author":"Neller","year":"2008","journal-title":"Semin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ni1071","article-title":"A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells","volume":"5","author":"Hou","year":"2004","journal-title":"Nat Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.4049\/jimmunol.1202282","article-title":"Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways","volume":"190","author":"Min","year":"2013","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.molimm.2006.12.020","article-title":"Regulation of the lifespan in dendritic cell subsets","volume":"44","author":"Chen","year":"2007","journal-title":"Mol Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/ijc.22377","article-title":"Enhancing dendritic cell vaccine potency by combining a BAK\/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments","volume":"120","author":"Kang","year":"2007","journal-title":"Int J Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg","year":"2015","journal-title":"Front Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/neuonc\/noy072","article-title":"Temozolomide for immunomodulation in the treatment of glioblastoma","volume":"20","author":"Karachi","year":"2018","journal-title":"Neuro Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/14712598.2017.1256388","article-title":"The importance of correctly timing cancer immunotherapy","volume":"17","author":"Beyranvand Nejad","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"798467","DOI":"10.1155\/2010\/798467","article-title":"Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity","volume":"2010","author":"Veltman","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00262-007-0305-4","article-title":"Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine","volume":"56","author":"Liu","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1136\/gut.2006.108621","article-title":"Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model","volume":"56","author":"Bauer","year":"2007","journal-title":"Gut"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00262-013-1407-9","article-title":"Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma","volume":"62","author":"Ghansah","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1172\/JCI68395","article-title":"IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity","volume":"123","author":"Carreno","year":"2013","journal-title":"J Clin Invest."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1207842","DOI":"10.1080\/2162402X.2016.1207842","article-title":"mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma","volume":"5","author":"Borch","year":"2016","journal-title":"Oncoimmunology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"eaao5931","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00262-004-0629-2","article-title":"Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide","volume":"54","author":"Holtl","year":"2005","journal-title":"Cancer Immunol Immunother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1479-5876-11-135","article-title":"Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients","volume":"11","author":"Ridolfi","year":"2013","journal-title":"J Transl Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00262-016-1905-7","article-title":"Phase I\/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma","volume":"65","author":"Akasaki","year":"2016","journal-title":"Cancer Immunol Immunother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11060-014-1635-7","article-title":"Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme","volume":"121","author":"Hunn","year":"2015","journal-title":"J Neurooncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1412901","DOI":"10.1080\/2162402X.2017.1412901","article-title":"Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide","volume":"7","author":"Pellegatta","year":"2018","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-14-0314","article-title":"Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I\/II-restricted epitopes for pancreatic cancer","volume":"20","author":"Koido","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/sj.bjc.6605935","article-title":"A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin\/capecitabine chemotherapy in colon cancer patients","volume":"103","author":"Lesterhuis","year":"2010","journal-title":"Br J Cancer"},{"key":"B67","first-page":"13146","article-title":"Immunomodulatory effect of DC\/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy","volume":"8","author":"Zhao","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12967-015-0473-5","article-title":"Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma","volume":"13","author":"Rozera","year":"2015","journal-title":"J Transl Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/CMR.0000000000000342","article-title":"Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma","volume":"27","author":"Fukuda","year":"2017","journal-title":"Melanoma Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jcyt.2017.01.007","article-title":"Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study","volume":"19","author":"Kongsted","year":"2017","journal-title":"Cytotherapy"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3892\/ol.2018.8734","article-title":"Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer","volume":"16","author":"Matsuda","year":"2018","journal-title":"Oncol Lett."},{"key":"B72","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14737175.2016.1202761","article-title":"Blood-brain barrier, cytotoxic chemotherapies and glioblastoma","volume":"16","author":"Dr\u00e9an","year":"2016","journal-title":"Expert Rev Neurother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1634\/theoncologist.12-9-1114","article-title":"Temozolomide for the treatment of metastatic melanoma: a systematic review","volume":"12","author":"Quirt","year":"2007","journal-title":"Oncologist"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e25962","DOI":"10.4161\/onci.25962","article-title":"Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment","volume":"2","author":"Kershaw","year":"2013","journal-title":"Oncoimmunology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fonc.2012.00095","article-title":"Role of T lymphocytes in tumor response to radiotherapy","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3978\/j.issn.2305-5839.2015.10.44","article-title":"Immunological interactions in radiotherapy-opening a new window of opportunity","volume":"4","author":"Bhattacharyya","year":"2016","journal-title":"Ann Transl Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/imr.12573","article-title":"Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences","volume":"280","author":"Brix","year":"2017","journal-title":"Immunol Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0b013e318163628c","article-title":"Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy","volume":"31","author":"Teitz-Tennenbaum","year":"2008","journal-title":"J Immunother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fimmu.2014.00102","volume":"5","author":"de la","year":"2014","journal-title":"Front Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol."},{"key":"B82","first-page":"6028","article-title":"Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer","volume":"59","author":"Chakravarty","year":"1999","journal-title":"Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/ijo.31.3.509","article-title":"Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94\/gp96 against squamous cell carcinoma in mice","volume":"31","author":"Akutsu","year":"2007","journal-title":"Int J Oncol."},{"key":"B84","first-page":"8466","article-title":"Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration","volume":"63","author":"Teitz-Tennenbaum","year":"2003","journal-title":"Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.clim.2007.02.005","article-title":"Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression","volume":"123","author":"Huang","year":"2007","journal-title":"Clin Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/CJI.0b013e3181a95165","article-title":"Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer","volume":"32","author":"Teitz-Tennenbaum","year":"2009","journal-title":"J Immunother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.imlet.2006.03.007","article-title":"Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma","volume":"106","author":"Lee","year":"2006","journal-title":"Immunol Lett."},{"key":"B88","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/gt.2008.161","article-title":"Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene","volume":"16","author":"Tatsuta","year":"2009","journal-title":"Gene Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/01.cji.0000154248.74383.5e","article-title":"Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma","volume":"28","author":"Chi","year":"2005","journal-title":"J Immunother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.ijrobp.2010.12.068","article-title":"Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients","volume":"82","author":"Finkelstein","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B91","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/emm.2006.56","article-title":"Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation","volume":"38","author":"Kim","year":"2006","journal-title":"Exp Mol Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CJI.0000000000000155","article-title":"A dendritic cell vaccine combined with radiotherapy activates the specific immune response in patients with esophageal cancer","volume":"40","author":"Wang","year":"2017","journal-title":"J Immunother."},{"key":"B98","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13014-016-0635-5","article-title":"Feasibility study of DCs\/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer","volume":"11","author":"Zhang","year":"2016","journal-title":"Radiat Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B100","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory Pathways in Immunotherapy for Cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"B104","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","article-title":"PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity","volume":"20","author":"Gato-Ca\u00f1as","year":"2017","journal-title":"Cell Rep."},{"key":"B106","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e1395124","DOI":"10.1080\/2162402X.2017.1395124","article-title":"Dendritic cell vaccine induces antigen-specific CD8(+) T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade","volume":"7","author":"Nagaoka","year":"2018","journal-title":"Oncoimmunology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e87059","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"key":"B109","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.canlet.2013.03.010","article-title":"Blockade of PD-1\/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice","volume":"336","author":"Ge","year":"2013","journal-title":"Cancer Lett."},{"key":"B110","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.leukres.2009.01.007","article-title":"B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10\/IL-12 production and generation of Treg cells","volume":"33","author":"Ge","year":"2009","journal-title":"Leuk Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00262-014-1563-6","article-title":"B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation","volume":"63","author":"Gibbons","year":"2014","journal-title":"Cancer Immunol Immunother."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS ONE"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.4049\/jimmunol.0900974","article-title":"TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination","volume":"183","author":"Pulko","year":"2009","journal-title":"J Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/JTO.0b013e31821c421d","article-title":"Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3","volume":"6","author":"Schneider","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.intimp.2014.02.027","article-title":"Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells","volume":"20","author":"Song","year":"2014","journal-title":"Int Immunopharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1189\/jlb.0813443","article-title":"Negative role of inducible PD-1 on survival of activated dendritic cells","volume":"95","author":"Park","year":"2014","journal-title":"J Leukoc Biol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/OTT.S65367","article-title":"Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro","volume":"7","author":"Wang","year":"2014","journal-title":"Onco Targets Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/2326-6066.CIR-16-0336","article-title":"Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion","volume":"5","author":"Van den Bergh","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00262-012-1334-1","article-title":"Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2217\/imt.15.80","article-title":"PDL-1\/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity","volume":"7","author":"Daneshmandi","year":"2015","journal-title":"Immunotherapy"},{"key":"B123","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/CJI.0000000000000071","article-title":"Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18","volume":"38","author":"Roeven","year":"2015","journal-title":"J Immunother."},{"key":"B124","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/intimm\/dxu076","article-title":"Therapeutic use of anti-CTLA-4 antibodies","volume":"27","author":"Blank","year":"2015","journal-title":"Int Immunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B127","doi-asserted-by":"publisher","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0762.","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers","author":"Sharma","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e1201625","DOI":"10.1080\/2162402X.2016.1201625","article-title":"Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination","volume":"5","author":"Boudewijns","year":"2016","journal-title":"Oncoimmunology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mrna electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J Clin Oncol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","volume":"5","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B133","article-title":"Combination therapy with a CD40-agonist and dendritic cell immunotherapy has synergistic effects in a murine mesothelioma model","author":"Lievense","year":"2015","journal-title":"J Thor Oncol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4049\/jimmunol.174.1.90","article-title":"Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells","volume":"174","author":"Prasad","year":"2005","journal-title":"J Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T16:19:02Z","timestamp":1662567542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":134,"alternative-id":["10.3389\/fimmu.2018.02759"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02759","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"article-number":"2759"}}